spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  KRAS  

 HSMN NewsFeed - 17 Jan 2025
FDA Approves LUMAKRAS(R) (Sotorasib) in Combination with Vectibix(R) (Panitumumab) for Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Oct 2024
Pillar Biosciences Receives CPT(R) Code for FDA Approved oncoReveal(TM) CDx Pan-Cancer Solid tumor IVD Kit
Diagnostics Oncology Reimbursement
 HSMN NewsFeed - 26 Dec 2023
Amgen Provides Regulatory Update on Status of Lumakras(R) (Sotorasib)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Nov 2023
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Aug 2022
Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Sep 2021
LUMAKRAS(TM) (Sotorasib) Combined With Vectibix(R) (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Apr 2021
Amgen Launches Biomarker Assist(TM), a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 23 Feb 2021
Elicio Therapeutics Announces FDA Clearance of IND application for ELI-002-- A Therapeutic Vaccine Targeting mutated KRAS Cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Dec 2020
Amgen's Sotorasib Granted Breakthrough Therapy Designation for Advanced or Metastatic Non-Small Cell Lung Cancer Patients with KRAS G12C Mutation
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 May 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Apr 2020
Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Aug 2019
Machavert Pharmaceuticals Signs Exclusive License Agreement to Control RAL GTPase Inhibitors against KRAS Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 17 Oct 2018
Thermo Fisher Scientific CE Marks Oncomine Dx Target Test
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 11 Sep 2017
Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Aug 2016
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Nov 2015
Rosetta Provides Update on Performance Data and Launch of RosettaGX Reveal(TM) (Thyroid microRNA Classifier)
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 29 May 2015
Transgenomic Launches EGFR CLIA Test That Accurately Detects Key Mutations in Solid and Liquid Patient Samples Using Multiplexed ICE COLD-PCR(TM)
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 26 May 2015
Roche receives FDA clearance for the cobas(R) Cdiff Test to detect Clostridium difficile
Diagnostics FDA
 HSMN NewsFeed - 11 May 2015
Roche Receives FDA Approval for cobas(R) KRAS Mutation Test
Diagnostics Oncology FDA
 HSMN NewsFeed - 6 Apr 2015
European Commission Approves Amgen's Vectibix(R) (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Mar 2015
Nimbus Therapeutics Raises $43 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 28 Apr 2014
Pfizer Confirms Prior Discussions with AstraZeneca Regarding a Possible Combination and Its Continuing Interest in a Possible Merger Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 Feb 2014
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Colorectal Cancer after Resection of Liver Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2014
Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Dec 2013
European Commission Approves Update of Erbitux Metastatic Colorectal Cancer Labeling to Patients With RAS Wild-Type Tumors
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Oct 2013
Health Canada Approves A New Treatment Option For Patients With Gastrointestinal Stromal Tumours (GIST), A Rare Form Of Sarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Oct 2013
IntegraGen Obtains Exclusive License for MicroRNA Which Predicts Therapy Outcomes in Metastatic Colorectal Cancer
Diagnostics Oncology Licensing
 HSMN NewsFeed - 30 Aug 2013
Bayer's Stivarga(R) (regorafenib) Tablets Approved in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2013
Lilly Debuts Early Oncology Pipeline Data At AACR Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Nov 2012
Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
Diagnostics Oncology
 HSMN NewsFeed - 29 Oct 2012
Bayer's Stivarga(R) (regorafenib) Tablets New Drug Application Granted Priority Review by U.S. FDA for the Treatment of Patients with Gastrointestinal Stromal Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Sep 2012
Bayer's Stivarga(R) (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jun 2012
Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2012
QIAGEN Receives FDA Clearances for Rotor-Gene Q MDx Instrument and Compatible Influenza A/B Assay
Diagnostics FDA
 HSMN NewsFeed - 18 Mar 2011
Amgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Mar 2011
Mira Dx(TM) Dismisses Flawed Study as “Puzzling,” and “Comparing Apples and Oranges”
Diagnostics Oncology
 HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Mar 2010
Merck Serono: Erbitux Granted Extended Use in Japan for 1st-Line Treatment of mCRC Patients with KRAS Wild-Type Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2010
Asuragen Appoints French Distributor Biomedical Diagnostics SA for Signature(R) Oncology Portfolio
Diagnostics Oncology Distribution
 HSMN NewsFeed - 21 Jan 2010
Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Nov 2009
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Sep 2009
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2009
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2008
NCCN Updates Guidelines for Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jul 2008
Clarient Launches New Colorectal Cancer Test
Diagnostics Oncology
 HSMN NewsFeed - 1 Jun 2008
Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Feb 2008
Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates
Biopharmaceuticals Licensing
 HSMN NewsFeed - 24 Jan 2008
KRAS Gene Status May Impact Vectibix(TM) (Panitumumab) Efficacy and Patient Reported Outcomes in Advanced Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Dec 2007
Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Sep 2007
New Biomarker Data Links KRAS Gene to Vectibix(TM) Clinical Response
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Sep 2007
Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union
Biopharmaceuticals Oncology Regulatory
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.